#1 Clinical Trials Search in Europe

Explore popular drugs in clinical trials

Check which drugs are currently being frequently studied.

See also our rare diseases glossary and popular diseases list.

Starting by letter

To open the drugs glossary, select a letter from the list below.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All drugs

Most popular drugs

The list below features the most popular substances currently involved in ongoing clinical trials.

Drug Trials
Pembrolizumab 446
Sodium Chloride 410
Carboplatin 334
Cisplatin 278
Paclitaxel 249
Fluorouracil 230
Oxaliplatin 222
Nivolumab 208
Dexamethasone 204
Rituximab 194
Cyclophosphamide 186
Durvalumab 162
Bevacizumab 160
Capecitabine 155
Paracetamol 154
Atezolizumab 146
Docetaxel 128
Prednisone 127
Tocilizumab 124
Prednisolone 119
Gemcitabine 116
Venetoclax 116
Etoposide 114
Mycophenolate Mofetil 113
Pemetrexed 112
Doxorubicin Hydrochloride 107
Lenalidomide 98
Infliximab 97
Ipilimumab 89
Folinic Acid 89
Acetylsalicylic Acid 88
Semaglutide 88
Placebo 84
Paclitaxel Albumin-Bound 83
Daratumumab 79
Cytarabine 79
Methotrexate 78
Fludarabine Phosphate 77
Calcium Folinate 76
Letrozole 72
Bortezomib 71
Olaparib 70
Gemcitabine Hydrochloride 69
Obinutuzumab 66
Azacitidine 66
Trastuzumab 65
Dapagliflozin 65
Cetuximab 64
Tacrolimus 62
Fulvestrant 62
Lenvatinib 62
Methylprednisolone 61
Irinotecan 60
Temozolomide 59
Irinotecan Hydrochloride Trihydrate 59
Vincristine Sulfate 57
Cemiplimab 56
Trastuzumab Deruxtecan 53
Enzalutamide 51
Apixaban 50
Betamethasone Sodium Phosphate 50
Dexamethasone Sodium Phosphate 49
Lidocaine Hydrochloride Monohydrate 49
Codeine Phosphate 48
Amoxicillin 47
Exemestane 46
Buclizine Hydrochloride 46
Potassium Chloride 46
Lidocaine Hydrochloride 46
Hydrocortisone 45
Anastrozole 45
Empagliflozin 45
Adalimumab 45
Ribociclib 44
Doxorubicin 43
Pertuzumab 43
Clavulanic Acid 42
Pomalidomide 42
Clopidogrel 42
Oxygen 42
Ibrutinib 41
Rivaroxaban 41
Tenofovir Alafenamide 41
Ruxolitinib 41
Abemaciclib 40
Atorvastatin 40
Bendamustine Hydrochloride 39
Carfilzomib 39
Ropivacaine Hydrochloride 39
Palbociclib 38
Trimethoprim 38
Ifosfamide 38
Metformin Hydrochloride 38
Pemetrexed Disodium 38
Propofol 38
Sulfamethoxazole 38
Dostarlimab 37
Acalabrutinib 37
Dexamethasone Phosphate 37
Linezolid 37

New drugs in trials

The list below features the new substances involved to ongoing clinical trials.

#1 VMX-C001

Clinical trials are studying VMX-C001 in people who take a Factor Xa direct oral anticoagulant and need urgent surgery or another high-bleeding-risk procedure.

3 weeks ago
#2 LIPASE

Clinical trials are investigating LIPASE, including a new lipase product compared with pancrelipase.

3 weeks ago
#3 TRIACYLGLYCEROL LIPASE

Clinical trials of TRIACYLGLYCEROL LIPASE are studying a new lipase treatment in adults with exocrine pancreatic insufficiency.

3 weeks ago
#4 IMA401

Clinical trials are investigating IMA401 in patients with recurrent and/or refractory solid tumors.

3 weeks ago
#5 ALLERGEN EXTRACTS

Clinical trials are studying BLOMIA TROPICALIS POLYMERIZED EXTRACT as part of a vaccine for dust mite and Blomia tropicalis allergy.

3 weeks ago
#6 AUR200

Clinical trials are investigating AUR200 in people with generalized myasthenia gravis.

3 weeks ago

Drugs starting by e

  • 1 

    E.coli Polysaccharide

    ,

    A clinical trial is underway to evaluate the effectiveness of E. coli Polysaccharide (OM-89) in reducing antibiotic consumption for patients with neurogenic bladder and recurrent urinary tract infections (UTIs). This study aims to compare the use of OM-89 against a placebo in patients with spinal cord injuries, focusing on antibiotic use, UTI incidence, hospitalization rates, and quality of life over a two-year period.

    Related diseases and areas:

  • 1 

    E2814

    ,

    E2814 is an investigational drug currently being studied in clinical trials for its potential to treat Alzheimer’s disease. This article provides an overview of the ongoing research into E2814, including its safety, efficacy, and potential benefits for patients with early-stage Alzheimer’s and those at risk for inherited forms of the disease.

    Related diseases and areas:

  • 4 

    Ebastine

    , , ,

    Ebastine, a histamine H1 receptor antagonist, is being studied in several clinical trials for its potential benefits in treating various conditions. This article examines the use of Ebastine in clinical trials for irritable bowel syndrome (IBS), metastatic castration-resistant prostate cancer, and urticaria. We’ll explore the drug’s effectiveness, dosage, and potential side effects across different medical applications.

    Related diseases and areas:

  • 1 

    Eclitasertib

    ,

    Eclitasertib, also known as SAR443122, is an investigational drug currently being studied in clinical trials for the treatment of moderate to severe ulcerative colitis. This article explores the ongoing research, potential benefits, and important information about Eclitasertib in clinical trials for patients with this inflammatory bowel disease.

    Related diseases and areas:

  • 2 

    Ecoo15

    ,

    Clinical trials are underway to evaluate the effectiveness of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (E. coli) disease in older adults. This vaccine, which contains the active substance ECOO15 among others, is being tested in adults aged 60 and older with a history of urinary tract infections. The trials aim to assess the vaccine’s ability to prevent serious E. coli infections and its safety profile.

    Related diseases and areas:

  • 2 

    Ecoo16

    ,

    Clinical trials are underway to evaluate the effectiveness of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (E. coli) disease in older adults. This vaccine, which contains the active substance ECOO16 among others, is being tested in adults aged 60 and older who have a history of urinary tract infections. The trials aim to assess the vaccine’s ability to prevent serious E. coli infections, its safety profile, and its impact on patients’ quality of life.

    Related diseases and areas:

  • 2 

    Ecoo18A

    ,

    Recent clinical trials are exploring the potential of ExPEC9V, a novel vaccine containing the ECOO18A component, in preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. These studies focus on evaluating the vaccine’s efficacy, safety, and immunogenicity in adults aged 60 and older, particularly those with a history of urinary tract infections. The trials aim to demonstrate the vaccine’s ability to reduce the incidence of invasive E. coli infections and improve the quality of life for vulnerable populations.

    Related diseases and areas:

  • 2 

    Ecoo1A

    ,

    Clinical trials are underway to evaluate the effectiveness of ExPEC9V, a new vaccine designed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults. These studies focus on adults aged 60 and above, particularly those with a history of urinary tract infections, as they are at higher risk for invasive E. coli infections. The trials aim to assess the vaccine’s ability to stimulate immune responses and protect against various forms of E. coli-related illnesses, including urinary tract infections and more severe invasive diseases.

    Related diseases and areas:

  • 2 

    Ecoo2

    ,

    This article discusses clinical trials investigating the use of ExPEC9V vaccine, which contains the active substance ECOO2, for preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in adults aged 60 and older. The trials aim to assess the vaccine’s efficacy, safety, and immune response, particularly in individuals with a history of urinary tract infections.

    Related diseases and areas:

  • 2 

    Ecoo25B

    ,

    ExPEC9V is an investigational vaccine being studied for its potential to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults. This article summarizes key information from two clinical trials evaluating the safety, efficacy, and immunogenicity of ExPEC9V in adults aged 60 and older, particularly those with a history of urinary tract infections. The trials aim to assess how well ExPEC9V can protect against serious E. coli infections when given alone or alongside a flu vaccine.

    Related diseases and areas:

  • 2 

    Ecoo4

    ,

    Clinical trials are currently underway to assess the effectiveness of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (E. coli) disease. This vaccine, which contains the active substance ECOO4 among others, is being tested in adults aged 60 and older who have a history of urinary tract infections. The trials aim to determine if ExPEC9V can safely reduce the occurrence of serious E. coli infections and related complications in this high-risk population.

    Related diseases and areas:

  • 2 

    Ecoo6A

    ,

    Recent clinical trials have been exploring the potential of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. This vaccine, which contains the active substance ECOO6A among others, is being tested in adults aged 60 and older with a history of urinary tract infections. The trials aim to evaluate the vaccine’s efficacy, safety, and ability to stimulate an immune response against various strains of E. coli that can cause serious infections outside the intestinal tract.

    Related diseases and areas:

  • 2 

    Ecoo75

    ,

    This article discusses clinical trials investigating the use of ExPEC9V, a vaccine containing the active substance ECOO75 (among others), for preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults. The trials aim to assess the vaccine’s efficacy, safety, and immune response in individuals aged 60 and above, particularly those with a history of urinary tract infections.

    Related diseases and areas:

  • 2 

    Ecopipam Hydrochloride

    ,

    Ecopipam Hydrochloride is an investigational drug being studied in clinical trials for its potential in treating Tourette’s Disorder and its effects on cardiac repolarization. These trials aim to assess the efficacy, safety, and tolerability of Ecopipam in various patient populations, including children, adolescents, and adults. The studies also evaluate the drug’s impact on heart function, providing crucial information for its development as a potential treatment option.

    Related diseases and areas:

  • 2 

    Ecubectedin

    , ,

    This article discusses the ongoing clinical trials of Ecubectedin (PM14), a promising drug being studied in combination with irinotecan for the treatment of various advanced solid tumors. The trials aim to determine the optimal dosage, evaluate safety and effectiveness, and explore potential biomarkers for treatment response. This research could potentially offer new hope for patients with difficult-to-treat cancers who have exhausted standard treatment options.

    Related diseases and areas:

  • 11 

    Eculizumab

    , , , , , ,

    Eculizumab, also known by its brand name Soliris, is a monoclonal antibody medication that has been the subject of numerous clinical trials for various medical conditions. This article explores the use of eculizumab in clinical trials for conditions such as kidney transplantation, neuromyelitis optica spectrum disorder (NMOSD), generalized myasthenia gravis (gMG), and others. We’ll examine the drug’s potential benefits, safety profile, and effectiveness across different patient populations.

    Related diseases and areas:

  • 3 

    Edg-5506

    , ,

    EDG-5506 is an investigational drug currently being studied in clinical trials for its potential to help people with muscular dystrophies, particularly Becker muscular dystrophy. This article explores the ongoing research on EDG-5506, including its mechanism of action, safety profile, and how it’s being tested in various clinical trials.

    Related diseases and areas:

  • 5 

    Edotreotide

    , , , , , ,

    This article examines the use of edotreotide, a radioactive drug, in clinical trials for diagnosing and treating neuroendocrine tumors (NETs). Edotreotide binds to somatostatin receptors expressed by NETs, allowing for targeted imaging and therapy. We’ll look at several studies evaluating edotreotide’s effectiveness compared to standard treatments for different types of NETs.

    Related diseases and areas:

  • 19 

    Edoxaban

    , , , , , , ,

    Edoxaban is an oral anticoagulant medication being studied in several clinical trials for its effectiveness and safety in treating various cardiovascular conditions. These trials are investigating edoxaban’s potential in preventing stroke in atrial fibrillation patients, resolving blood clots, and managing thrombosis in cancer patients. The studies aim to provide valuable insights into edoxaban’s real-world use and its impact on patient outcomes across different clinical scenarios.

    Related diseases and areas:

  • 5 

    Efanesoctocog Alfa

    , ,

    Efanesoctocog alfa, also known as BIVV001, is an innovative drug being studied in clinical trials for the treatment of hemophilia A. This article summarizes key information about ongoing trials evaluating the safety, efficacy, and long-term effects of efanesoctocog alfa in patients with hemophilia A. The trials aim to assess how well this new therapy can prevent and treat bleeding episodes, improve joint health, and enhance quality of life for people living with this bleeding disorder.

    Related diseases and areas:

  • 2 

    Efavirenz

    , ,

    Efavirenz, also known by brand names Sustiva and Stocrin, is an antiretroviral medication commonly used to treat HIV. Recent clinical trials have been exploring its potential uses beyond HIV treatment, including as a possible therapy for Alzheimer’s disease. This article summarizes key findings from several clinical trials investigating different aspects of efavirenz, from its pharmacokinetics to its effects on brain function and cholesterol metabolism.

    Related diseases and areas:

  • 2 

    Efepoetin Alfa

    ,

    Efepoetin Alfa, a novel long-acting erythropoietin-hybrid protein, is currently being studied in clinical trials for its potential in treating anemia, particularly in patients with chronic kidney disease. These trials aim to evaluate the drug’s effectiveness, safety, and tolerability in various patient populations, including healthy volunteers and those undergoing dialysis. The studies compare Efepoetin Alfa to existing treatments and assess its ability to improve hemoglobin levels and overall patient outcomes.

    Related diseases and areas:

  • 27 

    Efgartigimod Alfa

    , , , , , , , ,

    Efgartigimod Alfa, a promising drug in the field of autoimmune disorders, is currently being studied in various clinical trials. These trials aim to evaluate its safety and effectiveness in treating conditions such as Myasthenia Gravis, Guillain-Barré Syndrome, Optic Neuritis, and Neuromyelitis Optica Spectrum Disorders. The drug works by reducing harmful antibodies in the body, potentially offering new hope for patients with these challenging conditions.

    Related diseases and areas:

  • 2 

    Efinopegdutide

    ,

    Efinopegdutide, also known as MK-6024, HM12525A, or JNJ-64565111, is a promising drug currently being studied in clinical trials for its potential in treating various liver conditions, particularly nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). These trials aim to evaluate the drug’s safety, efficacy, and how well patients tolerate it. The studies focus on efinopegdutide’s ability to reduce liver fat content, improve liver function, and its effects on body weight and other metabolic parameters.

    Related diseases and areas:

  • 2 

    Efmoroctocog Alfa

    ,

    Efmoroctocog Alfa, also known as Eloctate, is an extended half-life factor VIII product being studied in clinical trials for the treatment of hemophilia A. These trials aim to evaluate its effectiveness in preventing and treating bleeding episodes, improving quality of life, and addressing challenges like inhibitor formation in patients with this rare blood clotting disorder.

    Related diseases and areas:

  • 1 

    Efpegerglucagon

    ,

    Efpegerglucagon, also known as HM15136, is being studied in clinical trials as a potential treatment for children aged 2 and older with Congenital Hyperinsulinism (CHI). This rare genetic condition causes excessive insulin production, leading to dangerously low blood sugar levels. The ongoing research aims to evaluate the safety, tolerability, and effectiveness of Efpegerglucagon in managing CHI symptoms and improving patients’ quality of life.

    Related diseases and areas:

  • 2 

    Efruxifermin

    ,

    Efruxifermin (EFX) is an innovative drug currently undergoing clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). These conditions are serious liver diseases associated with fat accumulation, inflammation, and fibrosis. The ongoing studies aim to evaluate the safety and efficacy of EFX in patients with various stages of liver disease, from non-cirrhotic to compensated cirrhosis. The trials are designed to assess improvements in liver health, metabolic parameters, and overall patient outcomes.

    Related diseases and areas:

  • 4 

    Eftilagimod Alfa

    ,

    Eftilagimod Alfa, also known as IMP321 or efti, is an innovative immunotherapy drug currently being studied in clinical trials for various types of cancer. This article explores the use of Eftilagimod Alfa in combination with other treatments, its potential benefits, and ongoing research efforts to improve cancer treatment outcomes.

    Related diseases and areas:

  • 1 

    Eftrenonacog Alfa

    ,

    This article discusses an 18-month clinical trial investigating the effectiveness of Eftrenonacog Alfa (ALPROLIX) in improving joint health for patients with hemophilia A and B. The study aims to assess joint outcomes using ultrasound technology, clinical evaluations, and patient-reported measures. This low-intervention trial provides valuable insights into the long-term effects of ALPROLIX on joint health and quality of life for individuals with hemophilia.

    Related diseases and areas:

  • 1 

    Efzofitimod

    ,

    Efzofitimod is an experimental drug being studied in clinical trials for various lung conditions, including systemic sclerosis-related interstitial lung disease (SSc-ILD), pulmonary sarcoidosis, and severe pneumonia related to COVID-19. These trials aim to evaluate the safety, efficacy, and tolerability of efzofitimod in patients with these challenging respiratory conditions.

    Related diseases and areas:

  • 1 

    EGANELISIB

    ,

    EGANELISIB (also known as IPI-549) is an innovative drug currently being investigated in multiple clinical trials for various types of cancer. As a first-in-class, oral immuno-oncology medication, EGANELISIB works by targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma. This mechanism helps to overcome immune suppression in the tumor microenvironment, potentially making cancer treatments more effective. The drug is being studied both as a monotherapy and in combination with other cancer treatments for conditions including acute myeloid leukemia, solid tumors, triple-negative breast cancer, renal cell carcinoma, and urothelial carcinoma. These trials aim to evaluate the safety, tolerability, and efficacy of EGANELISIB in patients with advanced cancers who need new treatment options.

    Related diseases and areas:

  • 1 

    Egl-001

    A groundbreaking clinical trial is underway to evaluate the potential of EGL-001, a new drug being tested for patients with advanced and/or metastatic solid tumors. This first-in-human study aims to assess the safety, tolerability, and preliminary effectiveness of EGL-001 when used alone or in combination with immunotherapy. The trial represents a significant step forward in the search for new treatment options for patients with difficult-to-treat solid tumors.

    Related diseases and areas:

  • 1 

    Eight Treg

    A groundbreaking clinical trial is underway to assess the safety and potential of “Eight Treg,” an innovative cell therapy for kidney transplant patients. This study aims to reduce dependence on traditional immunosuppressive drugs by using the patient’s own regulatory T cells to promote graft tolerance. The trial represents a significant step forward in transplant medicine, offering hope for improved long-term outcomes and reduced side effects for kidney transplant recipients.

    Related diseases and areas:

  • 1 

    Eik1003

    ,

    This article discusses the ongoing clinical trials of EIK1003 (also known as IMP1734), a novel PARP1 selective inhibitor being studied for the treatment of advanced solid tumors. The trials aim to evaluate the safety, tolerability, and effectiveness of EIK1003 as both a monotherapy and in combination with other anti-cancer agents. The study focuses on patients with various types of advanced cancers, including ovarian, breast, prostate, and pancreatic cancers.

    Related diseases and areas:

  • 11 

    Elacestrant

    ,

    Elacestrant is an emerging drug being studied in clinical trials for the treatment of advanced breast cancer, particularly in patients with estrogen receptor-positive (ER+) and HER2-negative tumors. This article explores the ongoing research and potential benefits of Elacestrant in various clinical settings, including its use as a single agent and in combination with other therapies.

    Related diseases and areas:

  • 3 

    Elacestrant Dihydrochloride

    , , ,

    Elacestrant Dihydrochloride, also known as RAD1901, is a promising drug being studied in various clinical trials. These trials aim to evaluate its effectiveness in treating different conditions, including breast cancer and menopausal symptoms like hot flashes. The studies range from early-phase pharmacokinetic assessments to more advanced trials combining Elacestrant with other cancer treatments. This article summarizes the key findings and objectives of these clinical trials, providing insights into the potential applications of Elacestrant in medical treatment.

    Related diseases and areas:

  • 3 

    Elafibranor

    , , , ,

    Elafibranor is an investigational drug being studied in clinical trials for various liver conditions, including nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). These trials aim to evaluate the safety, efficacy, and pharmacokinetics of elafibranor in different patient populations. The studies range from early phase 1 trials in healthy volunteers to larger phase 3 trials in patients with liver diseases.

    Related diseases and areas:

  • 1 

    Elamipretide Trihydrochloride

    ,

    Elamipretide Trihydrochloride is currently being studied in clinical trials as a potential treatment for dry age-related macular degeneration (dry AMD). This article explores the ongoing research, focusing on a Phase 3 clinical trial called ReNEW, which aims to evaluate the efficacy, safety, and pharmacokinetics of subcutaneous injections of Elamipretide in patients with dry AMD.

    Related diseases and areas:

  • 4 

    Elasomeran

    ,

    This article explores the use of Elasomeran, a key component in COVID-19 mRNA vaccines, in various clinical trials. These studies aim to assess the vaccine’s effectiveness, immune responses, and potential applications in different populations. The trials cover topics such as comparing high-dose and standard-dose influenza vaccines, investigating immune responses in COVID-19 recovered patients, and evaluating long-term immunity after vaccination.

    Related diseases and areas:

  • 6 

    Elebsiran

    ,

    This article explores the ongoing clinical trials investigating the use of Elebsiran (VIR-2218) for treating chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. Elebsiran is being studied alone and in combination with other therapies to assess its safety, efficacy, and potential to achieve functional cure in patients with these chronic viral liver infections.

    Related diseases and areas:

  • 1 

    Elenestinib Phosphate

    , ,

    Elenestinib Phosphate, also known as BLU-263, is an investigational drug currently being studied in clinical trials for the treatment of Indolent Systemic Mastocytosis (ISM) and Smoldering Systemic Mastocytosis (SSM). This article explores the ongoing research into Elenestinib Phosphate’s potential to improve outcomes for patients with these rare mast cell disorders.

    Related diseases and areas:

  • 1 

    Eletriptan

    ,

    Eletriptan, a second-generation serotonin receptor agonist, has been the subject of several clinical trials exploring its efficacy in treating migraines and other conditions. Originally approved for acute migraine treatment, recent studies have investigated its potential in addressing spinal cord injuries and menstrual migraines. This article summarizes key findings from clinical trials using Eletriptan, highlighting its effectiveness, safety profile, and potential new applications in medical treatment.

    Related diseases and areas:

  • 6 

    Elexacaftor

    , ,

    Elexacaftor, a groundbreaking drug used in combination therapy for cystic fibrosis (CF), has shown promising results in various clinical trials. This article explores the impact of elexacaftor-based treatments on different aspects of CF, including lung function, gastrointestinal issues, and overall quality of life for patients across different age groups.

    Related diseases and areas:

  • 1 

    Elezanumab

    ,

    Elezanumab, also known as ABT-555, is an investigational drug being studied in clinical trials for various neurological conditions. These trials aim to assess the safety and efficacy of Elezanumab in treating acute spinal cord injury, acute ischemic stroke, and multiple sclerosis. The drug is administered through intravenous infusion and is being evaluated for its potential to improve neurological function and promote neuroregeneration in patients with these challenging conditions.

    Related diseases and areas:

  • 1 

    Eliglustat Tartrate

    ,

    Eliglustat tartrate, also known as Genz-112638, is an oral medication being studied in clinical trials for the treatment of Gaucher disease, a genetic disorder that affects the body’s ability to break down certain fats. These trials aim to evaluate the efficacy, safety, and long-term effects of eliglustat tartrate in patients with different types of Gaucher disease, including those who have previously been treated with enzyme replacement therapy.

    Related diseases and areas:

  • 4 

    Elinzanetant

    , ,

    Elinzanetant is an investigational drug being studied for the treatment of vasomotor symptoms (hot flashes) associated with menopause. This article summarizes key information from multiple clinical trials evaluating the efficacy, safety, and pharmacokinetics of elinzanetant in postmenopausal women and other populations experiencing hormone-related hot flashes.

    Related diseases and areas:

  • 1 

    Elivaldogene Autotemcel

    ,

    This article discusses a clinical trial investigating the long-term effects of Elivaldogene Autotemcel, also known as eli-cel or Lenti-D Drug Product, in patients with Cerebral Adrenoleukodystrophy (CALD). The study aims to monitor both the safety and effectiveness of this treatment over an extended period, providing valuable insights into its use for this rare genetic disorder.

    Related diseases and areas:

  • 13 

    Elotuzumab

    , ,

    Elotuzumab is an innovative drug being studied in clinical trials for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. These trials aim to evaluate the safety and effectiveness of elotuzumab alone or in combination with other drugs in patients with relapsed or refractory multiple myeloma. The research explores various dosing regimens and combination therapies to improve outcomes for patients who have limited treatment options.

    Related diseases and areas:

  • 1 

    Elraglusib

    ,

    Elraglusib, also known as 9-ING-41, is an investigational drug being studied for the treatment of various types of cancer, including blood cancers and solid tumors. This article explores the ongoing clinical trials of Elraglusib, focusing on its potential benefits for patients with refractory (hard-to-treat) cancers and its use alone or in combination with other chemotherapy drugs.

    Related diseases and areas:

  • 16 

    Elranatamab

    , ,

    Elranatamab is an innovative bispecific antibody being studied in clinical trials for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. This article explores the ongoing research into elranatamab’s safety and efficacy across various stages of multiple myeloma, from newly diagnosed to relapsed/refractory cases.

    Related diseases and areas:

  • 4 

    Elritercept

    ,

    Elritercept, also known as KER-050, is an investigational drug being studied in clinical trials for the treatment of myelofibrosis (MF) and myelodysplastic syndromes (MDS). These trials aim to evaluate the safety, tolerability, and efficacy of elritercept in patients with anemia associated with these blood disorders. The studies are exploring elritercept as both a monotherapy and in combination with other treatments, offering hope for improved outcomes in patients with these challenging conditions.

    Related diseases and areas:

  • 1 

    ELTANEXOR

    , ,

    Eltanexor is an investigational drug currently being studied in clinical trials for patients with blood cancers that have not responded to previous treatments or have returned after initial improvement. A notable ongoing phase I trial is examining the combination of Eltanexor with another medication called Venetoclax for treating relapsed or refractory myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This study aims to determine the safety, appropriate dosage, and effectiveness of this drug combination. Eltanexor works by trapping tumor-suppressing proteins within cancer cells, potentially causing these cells to die or stop growing, while Venetoclax blocks a protein called BCL-2 that cancer cells need for survival.

    Related diseases and areas:

  • 3 

    Eltrombopag

    , ,

    Eltrombopag, a thrombopoietin receptor agonist, is being extensively studied in clinical trials for its potential to treat various blood disorders. This article explores the use of eltrombopag in conditions such as immune thrombocytopenia (ITP), aplastic anemia, and in enhancing platelet engraftment following cord blood transplantation. We’ll delve into the ongoing research, potential benefits, and safety considerations of this promising drug.

    Related diseases and areas:

  • 1 

    Elvn-002-1

    ,

    ELVN-002-1 is an investigational drug currently being studied in clinical trials for the treatment of HER2-positive solid tumors, including colorectal cancer and breast cancer. This article explores the ongoing research on ELVN-002-1 in combination with other cancer treatments, focusing on its potential benefits and safety profile for patients with advanced-stage cancers.

    Related diseases and areas:

  • 1 

    Emactuzumab

    ,

    Emactuzumab is an investigational drug being studied in clinical trials for the treatment of various types of cancer, including tenosynovial giant cell tumor (TGCT), solid tumors, and non-Hodgkin lymphoma. This article will explore the ongoing research on emactuzumab, its potential benefits, and its use in combination with other cancer therapies.

    Related diseases and areas:

  • 2 

    Emapalumab

    , , , ,

    Emapalumab is an innovative monoclonal antibody that targets and neutralizes interferon gamma (IFN-γ), a key cytokine involved in inflammation and immune responses. This article explores the ongoing clinical trials investigating emapalumab’s potential in treating various conditions, from rare diseases like hemophagocytic lymphohistiocytosis (HLH) to more common conditions like sepsis and cancer. These trials aim to assess the drug’s efficacy, safety, and optimal dosing regimens across different patient populations.

    Related diseases and areas:

  • 3 

    Emavusertib

    ,

    Emavusertib, also known as CA-4948, is an innovative drug being studied in clinical trials for the treatment of various hematologic malignancies, including acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and primary central nervous system lymphoma (PCNSL). These trials aim to evaluate the safety, efficacy, and optimal dosing of emavusertib, both as a monotherapy and in combination with other drugs, offering new hope for patients with relapsed or refractory forms of these challenging blood cancers.

    Related diseases and areas:

  • 1 

    Emedastine

    This article explores the use of Emedastine Difumarate Eye Drops in clinical trials for the treatment of allergic rhinitis. The study focuses on comparing the efficacy of allergen-specific immunotherapy with conventional drug treatments, including Emedastine, in managing symptoms of seasonal allergic rhinitis caused by Artemisia pollen.

    Related diseases and areas:

  • 1 

    Emibetuzumab

    ,

    Emibetuzumab, also known as LY2875358, is an investigational drug being studied in clinical trials for various types of cancer, including non-small cell lung cancer (NSCLC) and advanced cancers. These trials aim to evaluate the safety and efficacy of Emibetuzumab, both as a standalone treatment and in combination with other drugs such as Erlotinib and Ramucirumab. The studies focus on patients with specific biomarkers or those who have developed resistance to previous treatments, offering hope for new therapeutic options in cancer care.

    Related diseases and areas:

  • 7 

    Emicizumab

    ,

    Emicizumab is a novel bispecific antibody being studied as a treatment for hemophilia A in several clinical trials. These trials are evaluating the efficacy, safety, and pharmacokinetics of emicizumab in patients with hemophilia A, both with and without factor VIII inhibitors. The studies are examining different dosing regimens and patient populations, including adults, adolescents and young children. Key outcomes being assessed include bleeding rates, quality of life measures, and safety parameters.

    Related diseases and areas: